While targeting MCL-1 and BCL2L1 represents an attractive therapeutic combination, cobimetinib + VEN appeared to have modest clinical activity with significant toxicity, limiting the combination’s clinical application in AML. The gene discussed is MCL1; the disease is acute myeloid leukemia.